-- Advertisement --

£22bn Tory NHS cuts mean cancer & dementia treatments can now be denied to patients as “unaffordable”

-- Advertisement --

Stay in touch!

Sign up to be updated with Evolve's latest stories, and for opportunities to get involved.

Underfunding in the NHS means that ground-breaking treatments for cancer and dementia could be denied to patients on the grounds that they are “unaffordable”.

A number of dementia treatments are now in late-stage trials. If one proves successful in slowing the onset of the disease, and is subsequently approved by the National Institute of Health and Care Excellence (Nice), it will now be subject to a further “affordability” review by Health chiefs.

Advocates at NHS England claim that the review will not mean that access to life-saving medicines is denied or delayed because Nice will have to approve the terms of the restrictions as “reasonable”. But Nice also has affordability at its core.

All patients are legally entitled to treatments provided that they are approved by Nice as cost-effective. In real terms, this means that drugs are approved if they cost less than £30,000 for every year of good quality life they provide.

With the Tories’ planning to slash a further £22bn from the NHS budget by 2020, it is difficult to imagine that an extra affordability review will benefit patients.

The underfunding of the NHS is also compounded by the insatiable greed of pharmaceutical corporations. The NHS in England spent £15.5bn on medicines in 2014–2015 — a rise of 19.4% since 2010–2011.

If an effective treatment for cancer or dementia is discovered, patients could be left without treatment as the NHS struggles to shoulder the cost.

It has become commonplace to demand that NHS cuts and sell-offs be halted and reversed. But without also nationalising the pharmaceutical industry, bringing it under democratic workers’ control and management, the NHS will continue to be criminally overcharged for medicine.

-- Advertisement --

Evolve needs your help more than ever!

We rely on the generosity of our readers to help fund the majority of our work - but we need a little more to make ends meet and enable us to grow.

If we can reach 1,000 regular subscribers, we will become entirely financially sustainable - and we'll also have a little extra so we can build upwards and outwards to make our work have an even bigger impact.

In the last month alone, our work on the Environment Bill has helped force a change in the law for the better. And, since Evolve was founded, our uniquely viral style of journalism has repeatedly put the establishment on the back foot and helped force genuinely positive progression.

But we want to do far more - and we need your help to do it.

The best way you can help us is by becoming a Monthly or Annual subscriber. This kind of regular income allows us to better plan for the future - firstly so we can pay the bills, and then so we can set aside funds and time to work on extra projects.

However, if you can't commit to a regular payment, one-off donations - no matter how small - also make a big difference to us, and we genuinely make the most of every single penny.

So, if you appreciate the work that Evolve does and you want to see us make an even bigger impact on the world, please think about contributing to our work in whatever way you possibly can.

Tom D. Rogers

Co-Founder, Contributing Editor

Jess Miller

Co-Founder, Contributing Editor

Subscriber-Only Comments